Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06172426 | COMPLETED | Psoriatic Arthritis

Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry
Sponsor:

Novartis Pharmaceuticals

Brief Summary:

This was a retrospective cohort study to assess the incidence rate of psoriatic arthritis (PsA) among psoriasis (PsO) patients newly initiated on secukinumab or any biologics/apremilast (small molecule). The analysis was performed in two databases, IBM® MarketScan® database: Commercial Claims and Encounters (CCAE) and Medicare Supplemental Beneficiaries (MDCR) from 01 January 2010 to 30 June 2021 and BADBIR from 01 January 2016 to 01 September 2021.

Condition or disease

Psoriatic Arthritis

Psoriasis

Study Type : OBSERVATIONAL
Estimated Enrollment : 1171 participants
Official Title : Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry
Actual Study Start Date : 2022-11-17
Estimated Primary Completion Date : 2022-12-07
Estimated Study Completion Date : 2022-12-07

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
MarketScan® secukinumab cohort
  • Inclusion criteria
    • * Included patients with at least 1 secukinumab claim between 01 January 2015 and 30 June 2020 (index date is the first secukinumab claim)
    • * Included patients age ≥18 years as of the year of index date
    • * Included patients with at least 1 non-ruleout psoriasis diagnosis during 2 years of pre-index period
    • * Included patients with continuous medical/pharmacy coverage in the 2-year pre-index period
    • * Included patients with continuous medical/pharmacy coverage in the 1-year post-index period
    • Exclusion criteria
      • * Excluded patients with any psoriatic arthritis diagnosis during 2 years to 5 years pre-index period, as well as on the index date
      • * Excluded patients with any biologics/apremilast including secukinumab claim during the 2-year pre-index (excluding index date)
      • * Excluded patients received other non-secukinumab biologics/apremilast during 6 months post index date period (including index date) (This criterion is only applicable for the secukinumab cohort)
      • BADBIR cohort
        • Inclusion criteria
          • * Included non-switched patients with secukinumab treatment on or after the enrollment between 01 January 2017 to 01 September 2020
          • * Non-switched patients are those who did not use other biologics/apremilast treatments on the enrollment date
          • * Index date will be the date of the first secukinumab treatment date
          • * Included patients with age ≥ 18 on the index date
          • * Included patients with psoriasis diagnosis in the pre-index period and index date
          • * Included patients with ≥ 1 year follow-up period
          • * Follow-up period is the gap between patient's last visit date and index date
          • Exclusion criteria
            • * Excluded patients with psoriatic arthritis (PsA) prior to and on index date
            • * Excluded patients with any biologics/apremilast including secukinumab in the baseline period
Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry

Location Details

NCT06172426

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

Switzerland,

Novartis

Basel, Switzerland, 4002